Controlled trial of high doses of pemoline for adults with attention- deficit/hyperactivity disorder

Journal of Clinical Psychopharmacology

Volumn 19, Issue 3, 1999, Pages 257-264

  Wilens, Timothy E ^a   Biederman, Joseph ^a   Spencer, Thomas J ^a   Frazier, Jean ^a   Prince, Jefferson ^a   Bostic, Jeff ^a   Rater, Michael ^a   Soriano, Jennifer ^a   Hatch, Mary ^a   Sienna, Melissa ^a   Millstein, Rachael B ^a   Abrantes, Ana ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEMOLINE MAGNESIUM; PLACEBO;

ADULT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; DRUG TOLERABILITY; DYSPHORIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TIC; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PEMOLINE; TREATMENT OUTCOME;

EID: 0032955890     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199906000-00009     Document Type: Article

References (59)

1. Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up. I: psychiatric status. Arch Gen Psychiatry 1985;42:937-47.
2. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry 1985;24:211-20.
3. Biederman J, Faraone S, Milberger S, Curtis S, Chen L, Marrs A, Ouellette C, Moore P, Spencer T. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996;35:343-51.
4. Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1143-6.
5. Spencer T, Biederman J, Wilens TE, Faraone SV, Li T. Is attention deficit hyperactivity disorder in adults a valid diagnosis. Harv Rev Psychiatry 1994;1:326-35.
6. Millstein R, Wilens T, Biederman J, Spencer T. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Attention Disord 1997;2:159-65.
7. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Attention Disord 1996;1:147-61.
8. Biederman J, Faraone SV, Spencer T, Wilens TE, Norman D, Lapey KA, Mick E, Lehman B, Doyle A. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150:1792-8.
9. Levin FR, Kleber HD. Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry 1995;2:246-58.
10. Wilens T, Spencer T, Biederman J. Are attention-deficit hyperactivity disorder and the psychoactive substance use disorders really related? Harv Rev Psychiatry 1995;3:260-2.
11. Alpert J, Maddocks A, Nierenberg A, O'Sullivan R, Pava J, Worthington J, Biederman J, Rosenbaum J, Fava M. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996;62:213-9.
12. Wilens T, Spencer TJ, Biederman J. Pharmacotherapy of ADHD in adults. CNS Drugs 1998;9:347-56.
13. Wilens TE, Biederman J. The stimulants. In: Shafer D, ed. The psychiatric clinics of North America. Philadelphia: W. B. Saunders, 1992:191-222.
14. Swanson J, McBurnett K, Christian D, Wigal T. Stimulant medications and the treatment of children with ADHD. Adv Clin Child Psychol 1995;17:265-322.
15. Turnquist K, Frances R, Rosenfeld W, Mobarak A. Pemoline in attention deficit disorder and alcoholism: a case study. Am J Psychiatry 1983;140:622-4.
16. Zaczek R, Battaglia G, Contrera JF, Culp S, DeSouza EB. Methyl-phenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol Appl Pharmacol 1989;100:227-33.
17. Collier CP, Soldin SJ, Swanson JM, MacLeod SM, Weinberg F, Rochefort JG. Pemoline pharmacokinetics and long-term therapy in children with attention deficit disorder and hyperactivity. Clin Pharmacokinet 1985;10:269-78.
18. Langer DH, Sweeney KP, Bartenbach DE, Davis PM, Menander KB. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 1986;17:213-27.
19. Weiss RD, Pope HG, Mirin SM. Treatment of chronic cocaine abuse and attention deficit disorder, residual type, with magnesium pemoline. Drug Alcohol Depend 1985;15:69-72.
20. Pratt DS, Dubois RS. Hepatotoxicity due to pemoline (Cylert): a report of two cases. J Pediatr Gastroenterol Nutr 1990;10:239-41.
21. Nehra A, Mullick F, Ishak KG, Zimmerman HJ. Pemoline-associated hepatic injury. Gastroenterology 1990;99:1517-9.
22. Physician's Desk Reference: PDR, 1995. Montvale, NJ: Medical Economics Data Production Company, 1995.
23. Conners CK, Taylor E. Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Arch Gen Psychiatry 1980;37:922-30.
24. Sallee FR, Stiller RL, Perel JM. Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1992;31:244-51.
25. Page JG, Bernstein JE, Janicki RS, Michelli FA. A multi-clinic trial of pemoline in childhood hyperkineses. In: Connors CK, eds. Clinical uses of stimulant drugs in children. Amsterdam: Excerpta Medical, 1974:98-124.
26. Bostic J, Biederman J, Spencer T, Wilens T, Prince J. A double-blind comparison of pemoline and placebo for adolescents with ADHD. Scientific Meetings of the American Academy of Child and Adolescent Psychiatry. Toronto, Ontario, 1997.
27. Pelham WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methyl-phenidate sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86:226-37.
28. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry 1976;33:1453-60.
29. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder ("minimal brain dysfunction") in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry 1981;38:449-56.
30. Spencer T, Wilens TE, Biederman J, Faraone SV, Ablon S, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.
31. Spitzer RL, Williams JB, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R - Non-Patient Edition (SCID-NP, Version 1:0). Washington, DC: American Psychiatric Press, 1990.
32. Orvaschel H. Psychiatric interviews suitable for use in research with children and adolescents. Psychopharmacol Bull 1985;21: 737-48.
33. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:885-90.
34. Wechsler D. Manual for the Wechsler Adult Intelligence Scale-Revised. San Antonio: The Psychological Corporation, 1981.
35. Jastak JF, Jastak S. The Wide Range Achievement Test-Revised. Wilmington, DE: Jastak Associates, 1985.
36. Faraone SV, Santangelo S. Methods in genetic epidemiology. In: Fava M, Rosenbaum JF, eds. Research designs and methods in psychiatry. Amsterdam: Elsevier, 1992:93-118.
37. Hollingshead AB. Four factor index of social status. New Haven: Yale University Department of Sociology, 1975.
38. Wilens T, Biederman J, Prince J, Spencer T, Schleifer D, Harding M, Linehan C, Hatch M. A double-blind, placebo-controlled trial of desipramine for adults with ADHD. Am J Psychiatry 1996;153: 1147-53.
39. Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Hatch M, Harding M. Tolerability and efficacy of tomoxetine for adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155: 693-5.
40. National Institute of Mental Health. CGI (Clinical Global Impression Scale)-NIMH. Psychopharmacol Bull 1985;21:839-44.
41. Barkley RA. Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: Guilford Press, 1990.
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
43. Beck AT, Ward CE, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-71.
44. Hamilton M The assessment of anxiety states by rating. Br J Med Psychology 1959;32:50-5.
45. Seidman LJ, Biederman J, Weber W, Hatch M, Faraone S. Neuropsychological functioning in adults with ADHD. Biol Psychiatry 1998;44:260-8.
46. Weintraub S, Mesulam MM. Mental state assessment of young and elderly adults in behavioral neurology. In: Mesulam MM, eds. Principles of Behavioral Neurology. Philadelphia: F. A. Davis Co., 1985:71-123.
47. Golden CJ. Stroop Color and Word Test: a manual for clinical and experimental use. Chicago: Stoelting, Co., 1978.
48. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sort Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources, Inc., 1993.
49. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea T, Imber SD, Sotsky SM, Watkins JT. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993;50:739-50.
50. Bailor JC, Mosteller F. Medical Uses of Statistics. Waltham, MA: New England Journal of Medicine Books, 1986.
51. Stein MA, Sandoval R, Szumowski E, Roizen N, Reinecke MA, Blondis TA, Klein Z. Psychometric characteristics of the Wender Utah Rating Scale: reliability and factor structure for men and women. Psychopharmacol Bull 1995;31:423-31.
52. Knights RM, Viets CA. Effects of pemoline on hyperactive boys. Pharmacol Biochem Behav 1975;3:1107-14.
53. Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1995;34:886-96.
54. Wilens T, Spencer TJ. Pharmacology of amphetamines. In: Tarter RE, Ammerman RT, Ott PJ, eds. Handbook of substance abuse: neurobehavioral pharmacology. New York: Plenum Press, 1998: 501-13.
55. Zametkin AJ, Rapoport JL. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 1987;26:676-86.
56. Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 1990;48:57-66.
57. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, Kennedy JL. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996;1:121-4.
58. Ashgari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van-Tol H. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995;65: 912-5.
59. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1995;57:184-9.